Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 4/20 | 0.53 |
| ▸ | PARG | Q86W56 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | DDO | Q99489 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359339 | 0.86 | GRIA1 (0.57) | GRIA1GRIA2GRIA3GRIA4DAO | |
| SCHEMBL7220155 | 0.81 | DAO (0.66) | DAOADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL21848191 | 0.81 | GRIA1 (0.56) | GRIA1GRIA2GRIA3GRIA4PARG | |
| SCHEMBL9395750 | 0.81 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4DAO | |
| SCHEMBL30770202 | 0.81 | GRIA1 (0.56) | GRIA1GRIA2GRIA3GRIA4DAO | |
| SCHEMBL9364597 | 0.81 | DAO (0.70) | DAOADORA3ADORA1DDOCA12 | |
| Hydrochloric Acid SCHEMBL27488313 | 0.79 | GRIA1 (0.54) | GRIA1GRIA2GRIA3GRIA4PARG | |
| SCHEMBL9395728 | 0.78 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4PARG | |
| SCHEMBL29212235 | 0.78 | GRIA1 (0.66) | GRIA1GRIA2GRIA3GRIA4PARG | |
| SCHEMBL30898295 | 0.78 | GRIA1 (0.66) | GRIA1GRIA2GRIA3GRIA4PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| EP-3640247-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20050148586-A1 | Quinoxalinones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148586-A1 | Quinoxalinones | SLC5A2, GPR119, GLS2 | GRIA1 2287/4885GRIA2 2073/4885GRIA3 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.